Trial Profile
A Study Evaluating Salvage Combination Of Ipilimumab and Nivolumab in Advanced Melanoma Patients after Failure of Prior Checkpoint Inhibitor Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2017
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 29 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.